Biogen results rise, but miss 1Q forecasts

April 24, 2015 1:34 PM

60 0

Biogen Idec Inc. reported lower-than-expected profit and revenue for the first quarter on slower sales growth of its multiple sclerosis drug Tecfidera.

The biotechnology company reported its first-quarter profit climbed 71 percent to $822.5 million, or $3.49 per share. Earnings, adjusted for one-time gains and costs, were $3.82 per share.

Read more

To category page